Trial Profile
A Prospective, Multicentre Trial to assess the safety & effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Long Lesion (24 - 34mm in length)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms PLATINUM-LL
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 23 Oct 2012 Two-year results were presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, and were reported in a Boston Scientific Corporation media release.
- 18 Oct 2012 Two-year results will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics scientific symposium, according to a Boston Scientific Corporation media release.